Insulet Corp
XMUN:GOV
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
I
|
Insulet Corp
XMUN:GOV
|
US |
|
A
|
Alarm.com Holdings Inc
XBER:3RL
|
US |
Insulet Corp
Insulet makes wearable insulin delivery systems for people with diabetes. Its main product is the Omnipod line, a small tubeless pump that sticks to the body and automatically delivers insulin without the need for repeated injections. The company also provides the disposable pods, the controller or app that manages dosing, and training and support for patients and healthcare providers. Its main customers are people with type 1 diabetes and some people with type 2 diabetes who need insulin therapy, along with hospitals, clinics, and prescribing doctors who help choose the device. Insulet earns money mostly by selling the pods that must be replaced regularly, along with the starter systems and related supplies that go with them. That creates a recurring revenue model tied to continued patient use rather than one-time equipment sales. What makes Insulet different is that it is not a broad medical device company; it is focused on a single category of diabetes care: tubeless automated insulin delivery. In the insulin pump market, it sits between drug makers that supply insulin and the healthcare providers who prescribe diabetes technology, giving it a specialized role in a treatment workflow that patients use every day.
Insulet makes wearable insulin delivery systems for people with diabetes. Its main product is the Omnipod line, a small tubeless pump that sticks to the body and automatically delivers insulin without the need for repeated injections. The company also provides the disposable pods, the controller or app that manages dosing, and training and support for patients and healthcare providers.
Its main customers are people with type 1 diabetes and some people with type 2 diabetes who need insulin therapy, along with hospitals, clinics, and prescribing doctors who help choose the device. Insulet earns money mostly by selling the pods that must be replaced regularly, along with the starter systems and related supplies that go with them. That creates a recurring revenue model tied to continued patient use rather than one-time equipment sales.
What makes Insulet different is that it is not a broad medical device company; it is focused on a single category of diabetes care: tubeless automated insulin delivery. In the insulin pump market, it sits between drug makers that supply insulin and the healthcare providers who prescribe diabetes technology, giving it a specialized role in a treatment workflow that patients use every day.
Strong start: Insulet said first-quarter revenue rose 30% on a constant-currency basis to $762 million, with growth across both the U.S. and international markets.
Guidance raised: Management lifted full-year 2026 total company revenue growth guidance to 21% to 23% from 20% to 22%, citing momentum in both regions.
Margins improved: Adjusted operating margin expanded 110 basis points to 17.5%, and adjusted EPS rose about 40% to $1.42.
U.S. seasonality: The company said U.S. new customer starts were softer sequentially because of deductible resets and possible ACA-related effects, but trends improved through April.
Innovation pipeline: Insulet highlighted this quarter’s algorithm upgrade, Libre 3 Plus integration, a 2027 Omnipod 6 launch, and first patient enrollment in its fully closed-loop type 2 study.
Pricing and access: Management said U.S. pricing remained positive, expects rational pharmacy-channel behavior, and continues to expand coverage and access in the U.S., Canada, and Europe.
Quality event: The company said the March medical device correction did not appear to hurt new customer starts, and it has already implemented targeted manufacturing fixes.
